Forbes reported in 2022 that “companies find themselves offering remote and hybrid options as a strategy for retaining talent rather than for any performance considerations – after all, you can’t boost employee efficiency if you
2021 saw record venture capital investment and IPO activity in biotech. One hundred forty-seven companies went public and valuations soared. In 2022 only 25 companies went public and most biotech index funds are down more
Why is it so difficult to figure out drug pricing, and what is forecast to happen with drug pricing in 2023? Smith Hanley offers our interpretation. The median wholesale acquisition cost (WAC) for brand drugs
The Covid-19 pandemic accelerated the digital transformation in the pharmaceutical industry. Andrew Mar, Associate Director, HCP Marketing Biologics at Sun Pharmaceutical, says, “There are long-lasting changes that will come out of this pandemic. The ability
The movement of talent through voluntary resignation and reorgs has hit every corner of the business world, and the pharma industry is no exception. Leaders across the BioPharma industry say they are struggling to find
Coming out of the global COVID-19 pandemic, the future holds both opportunity and increased complexity for the clinical life sciences industry. Precision Medicine is Making Waves The development of genetic-based precision formulas will impact the
